Stable Coronary Artery Disease

6

Review clinical trials related to Stable Coronary Artery Disease. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

A Study to See How RO7763505 Works and How Safe it is When Given to Healthy People and People With Stable Heart Disease

This study will evaluate safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of single ascending doses (SAD) (Part 1a), multiple ascending doses (MAD) (Part 1b), and the food effect (Part 1c) of RO7763505 in healthy adult participant. In Part 2, the safety, tolerability, PK and PD of multiple doses of RO7763505 in participants with stable coronary artery diseases (CAD).

Participants needed: 196
Trial details
Phase: Phase 1Age: 18-75Biological sex: AllType: InterventionalSponsor: Hoffmann-La RocheUpdated: Jul 13, 2026Locations: 1
Eligibility criteria

Healthy biologically male and female participants of nonchildbearing potential o... [+5]

Any condition or disease detected during the medical interview/physical examinat... [+5]

Status: Not yet recruiting

A Study to Learn About How Safe Nitroglycerin is and How it Affects the Body When Taken Along With Nurandociguat in People With Coronary Artery Disease

This study is designed to find out how safe nitroglycerin is and how it affects the body when it is taken together with another medicine called nurandociguat in people who have coronary artery disease (CAD). CAD is a condition where the arteries that supply blood to the heart become narrowed or blocked, often causing chest pain or even heart attacks. Many people with CAD also have chronic kidney disease (CKD), a long-term condition where the kidneys do not work as well as they should. People with CAD often use nitroglycerin to help improve blood flow to the heart. Nurandociguat is a new medicine being studied to help people with CKD by widening blood vessels and improving blood flow. Both nitroglycerin and nurandociguat work in similar ways in the body, so taking them together could have a stronger effect on blood vessels. This might lead to a sudden drop in blood pressure or other side effects. The main goal of this study is to learn how safe it is to use nitroglycerin and nurandociguat together, and to understand how they interact in the body.

Participants needed: 36
Trial details
Phase: Phase 1Age: 40-80Biological sex: AllType: InterventionalSponsor: BayerUpdated: Jun 25, 2026Locations: 5
Eligibility criteria

Participant must be 40 to 80 years of age inclusive at the time of signing the i... [+3]

Ejection fraction less than 30 percent at screening as determined by echocardiog... [+9]

Status: Recruiting

A Study to See How RO7763505 Works and How Safe it is When Given to Healthy People and People With Stable Heart Disease

This study will evaluate safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of single ascending doses (SAD) (Part 1a), multiple ascending doses (MAD) (Part 1b), and the food effect (Part 1c) of RO7763505 in healthy adult participant. In Part 2, the safety, tolerability, PK and PD of multiple doses of RO7763505 in participants with stable coronary artery diseases (CAD).

Participants needed: 196
Trial details
Phase: Phase 1Age: 18-75Biological sex: AllType: InterventionalSponsor: Hoffmann-La RocheUpdated: Jun 15, 2026Locations: 1
Eligibility criteria

Healthy biologically male and female participants of nonchildbearing potential o... [+5]

Any condition or disease detected during the medical interview/physical examinat... [+5]

Status: Recruiting

Local And Systemic Macrophage Activation in Coronary and Peripheral Artery Disease

Numerous clinical studies have highlighted the role of macrophages in the destabilization of coronary lesions; however, there is limited literature on the relationship between circulating monocytes and intraplaque macrophages. This study aims to evaluate and compare the presence of macrophages and their subsequent activation within coronary and peripheral atherosclerotic lesions, and to correlate these findings with the distribution of circulating monocyte subpopulations.

Participants needed: 60
Trial details
Age: 18+Biological sex: AllType: InterventionalSponsor: Maria Cecilia HospitalUpdated: May 14, 2026Locations: 1
Eligibility criteria

Patients with chronic coronary artery disease; [+3]

Severe renal dysfunction [+7]

Status: Not yet recruiting

Coronary Laser Atherectomy Registry From an International Taskforce

This study is a prospective, investigator-initiated, multi-center, single arm, observational registry of performance of Excimer Laser Coronary Atherectomy (ELCA) in standard use cases of percutaneous coronary intervention (PCI).

Participants needed: 500
Trial details
Age: 18+Biological sex: AllType: ObservationalSponsor: Ceric SàrlUpdated: Jan 16, 2026
Eligibility criteria

Age 18 years or over [+8]

Pregnant or breast feeding [+6]

Status: Recruiting

MCG is Clinically Applied to Evaluate Myocardial Ischemic Function in Patients With Stable Coronary Artery Disease

The objective of this observational study is to evaluate the diagnostic effectiveness of magnetocardiography (MCG) in patients with stable coronary artery disease (SCAD) and compare it with coronary CTA (CCTA). Additionally, the study aims to determine the most suitable diagnostic index for MCG. The primary question it seeks to address is whether MCG or MCG combined with CCTA can be utilized to guide the clinical application of percutaneous coronary intervention (PCI) for coronary heart disease.

Participants needed: 291
Trial details
Age: 18+Biological sex: AllType: ObservationalSponsor: Nanhai Hospital, Guangdong Provincial People's HospitalUpdated: Jun 4, 2024Locations: 1Duration: 1 Year
Eligibility criteria

Age ≥18 years old. [+2]

Patients diagnosed with acute coronary syndrome. [+11]